{"entity":{"id":"itil-306","kind":"drug","name":"ITIL-306","aka":["CoStAR-TIL"],"tldr":"ITIL-306 is an autologous tumour-infiltrating lymphocyte cell therapy with a co-stimulatory antigen receptor from Instil Bio that reached phase 1 for epithelial ovarian cancer, non-small cell lung cancer and renal cell carcinoma; development has stopped.","summary":"ITIL-306 (CoStAR-TIL) is an autologous tumour-infiltrating lymphocyte (TIL) cell therapy with a co-stimulatory antigen receptor (CoStAR) from Instil Bio. A cell therapy made from the patient's own tumour-infiltrating lymphocytes that carries a molecule designed to increase TIL activity when it meets folate receptor alpha (FOLR1) on the tumour. Its furthest stage is phase 1, for epithelial ovarian cancer, non-small cell lung cancer and renal cell carcinoma. ClinicalTrials.gov registers it in one study linked below. Form 10-K for 2025 says the ITIL-306 trials were discontinued; NCT05397093 TERMINATED. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Instil Bio: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05397093"},{"label":"Instil Bio: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000019/til-20251231.htm"},{"label":"Instil Bio: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000019/til-20251231.htm"},{"label":"ClinicalTrials.gov: trials of ITIL-306","url":"https://clinicaltrials.gov/search?intr=ITIL-306"}],"tags":["pipeline","ctgov-ingest","discontinued"],"related":[],"cancers":["ovarian","nsclc","rcc"],"sections":[],"technologies":[],"targets":["folr1"],"drugs":[],"companies":["instil-bio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05397093"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ITIL-306","modality":"Autologous tumour-infiltrating lymphocyte (TIL) cell therapy with a co-stimulatory antigen receptor (CoStAR)","mechanism":"A cell therapy made from the patient's own tumour-infiltrating lymphocytes that carries a molecule designed to increase TIL activity when it meets folate receptor alpha (FOLR1) on the tumour.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/itil-306/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"target":[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"}],"company":[{"id":"instil-bio","kind":"company","name":"Instil Bio","route":"/companies/instil-bio/"}],"trial":[{"id":"nct05397093","kind":"trial","name":"ITIL-306 in Advanced Solid Tumors","route":"/trials/nct05397093/"}]}}